SYDNEY, June 9, 2026, 23:01 (AEST)
- Cochlear shares closed at A$102.64, rising 2.18%, after trading resumed on the ASX cash market following the King’s Birthday holiday Monday.
- S&P/ASX 200 edged down 0.24% to 8,604.20. Cochlear outperformed the index.
- The stock remains well under last year’s high. April’s profit warning reset where the market saw earnings.
Cochlear Ltd shares gained on Tuesday, trading above A$100. The hearing-implant maker has clawed back some ground after April’s record selloff, which followed an earnings downgrade.
Shares last changed hands at A$102.64 in Sydney, adding A$2.19, or 2.18%, at 4:10 p.m. The day saw around 690,000 shares traded. The stock moved between A$100.56 and A$103.75.
ASX trading returned Tuesday after the King’s Birthday holiday closed markets on Monday. Investors got a clear look at Cochlear after its late-week rally, but the S&P/ASX 200 still closed lower. Healthcare names firmed, but that wasn’t enough to cover lost ground in mining stocks.
Cochlear didn’t release any new earnings news on Tuesday. The most recent price-sensitive statement was the April 22 trading update, according to market data. A June 9 filing showed up, but it was just a “Becoming a substantial holder” notice. This means a big investor hit the disclosure threshold, which investors tend to watch for shifts in ownership—not for earnings updates. Intelligent Investor
April’s update is still weighing on the stock. Cochlear lowered its FY26 underlying net profit guidance to A$290 million to A$330 million, down from the earlier A$435 million to A$460 million target. The company blamed weaker developed-market implant sales, Middle East uncertainty, a stronger Australian dollar and changes to its cost base.
Cochlear shares sank almost 41% on April 22, closing at their lowest since March 2016, after it warned on slack demand and disruption tied to Middle East conflict, Reuters reported at the time. Jefferies analysts said there appeared to be “volume delays,” and questioned if the issue was structural. Reuters
Cochlear CEO Dig Howitt has told investors to focus on the company’s market standing and product pipeline. In an April update, he said Cochlear “remain[s] confident of our market leadership” and highlighted uptake of the Nucleus Nexa system. He also said there’s a growing “clinical need” for implants.
The company reported third-quarter services revenue rose 13% in constant currency. This metric removes swings in exchange rates, which can matter for global firms when the Australian dollar shifts a lot.
Cochlear ended higher against a softer market, with the move standing out. CSL finished up 1.59% and Pro Medicus inched 0.09% higher on the ASX, giving some cover to the trade.
The downgrade didn’t land as just a slight miss for analysts and investors. Anna Milne, who manages portfolios at Wilson Asset Management, said the size of the cut and uncertainty around recovery “shocked the market.” Steve Wheen at Jarden called the move “far worse than anticipated,” according to a report republished by Wilson Asset Management. Wilson Asset Management
Risks are still front and center. Hospital capacity pressure in Europe, soft referral flows from hearing-aid networks, U.S. consumers holding back, or delays shipping to the Middle East could all stop the recovery in its tracks before August numbers. Cochlear is also warning about as much as A$10 million at risk from receivables, around A$18 million to A$25 million in restructuring costs, and about A$25 million after tax from currency swings in the second half.
Cochlear stock is back over A$100 for now, but it’s still a long way from its old premium. Shares sit about 68% under the 52-week high and up about 14% from the April low. The next earnings update will be the real test.
